SCHEMBL4906508

SCHEMBL4906508

CCN(c1coc(-c2ccc(C(F)(F)F)cc2)n1)S(=O)(=O)c1ccc(C)c(C(=O)O)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.41
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
PPARG P37231 3/20 0.38
PPARA Q07869 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ACLY P53396 1/20 0.38
USP2 O75604 1/20 0.38
TRPM8 Q7Z2W7 2/20 0.38
HDAC8 Q9BY41 2/20 0.38
HDAC3 O15379 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
PPARD Q03181 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
KDM1A O60341 1/20 0.37
RXRA P19793 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4897582 0.92 LMNA (0.40) LMNAALDH1A1HPGDALOX15HSD17B10
SCHEMBL4906847 0.91 ALDH1A1 (0.38) LMNAALDH1A1PPARGPPARASMN1; SMN2
SCHEMBL4900885 0.91 PPARG (0.43) LMNAALDH1A1HPGDALOX15HSD17B10
SCHEMBL4911906 0.90 HDAC8 (0.39) LMNAALDH1A1HPGDALOX15HSD17B10
SCHEMBL4903608 0.84 PPARG (0.41) LMNAALDH1A1PPARGPPARASMN1; SMN2
SCHEMBL4895709 0.83 TP53 (0.43) LMNAALDH1A1HPGDALOX15HSD17B10
SCHEMBL4903873 0.83 HDAC8 (0.38) ALDH1A1PPARGPPARASMN1; SMN2USP2
SCHEMBL4900715 0.83 ALDH1A1 (0.39) LMNAALDH1A1HPGDALOX15HSD17B10
SCHEMBL4903714 0.82 LMNA (0.56) LMNAALDH1A1HPGDALOX15HSD17B10
SCHEMBL4899823 0.82 LMNA (0.40) LMNAALDH1A1HPGDALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765796-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS Pfizer Products Inc. (US) 2007-03-28 EP claimed
WO-2006003495-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2006-01-12 WO claimed
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-12-29 US claimed
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD LMNA 319/4885ALDH1A1 2956/4885HPGD 724/4885
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PPARA, PPARG, PPARD LMNA 319/4885ALDH1A1 2956/4885HPGD 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.